A5074653078- Cancer Genomics and Diagnostics
- Genetic factors in colorectal cancer
- Colorectal Cancer Treatments and Studies
- Gastric Cancer Management and Outcomes
- Lung Cancer Treatments and Mutations
- Health and Medical Research Impacts
- MicroRNA in disease regulation
- HER2/EGFR in Cancer Research
- Mathematical Biology Tumor Growth
- Breast Cancer Treatment Studies
- Cancer Immunotherapy and Biomarkers
- Circular RNAs in diseases
- Neutropenia and Cancer Infections
- Cancer Treatment and Pharmacology
- Esophageal Cancer Research and Treatment
- Colorectal and Anal Carcinomas
- Renal and related cancers
- Renal cell carcinoma treatment
- Cancer-related molecular mechanisms research
- Radiomics and Machine Learning in Medical Imaging
- Monoclonal and Polyclonal Antibodies Research
- Advanced Breast Cancer Therapies
- Urologic and reproductive health conditions
- Genital Health and Disease
- Cancer Diagnosis and Treatment
Royal Marsden NHS Foundation Trust
2014-2024
Royal Marsden Hospital
2014-2024
Institute of Cancer Research
2016-2024
Creative Research Enterprises (United States)
2018
Charing Cross Hospital
2012-2013
Imperial College London
2013
Cancer organoids to model therapy response are miniature, three-dimensional cell culture models that can be made from primary patient tumors and studied in the laboratory. Vlachogiannis et al. asked whether such “tumor-in-a-dish” approaches used predict drug responses clinic. They generated a live organoid biobank patients with metastatic gastrointestinal cancer who had previously been enrolled phase I or II clinical trials. This allowed authors compare how actually responded Encouragingly,...
Sequential profiling of plasma cell-free DNA (cfDNA) holds immense promise for early detection patient progression. However, how to exploit the predictive power cfDNA as a liquid biopsy in clinic remains unclear. RAS pathway aberrations can be tracked monitor resistance anti-EGFR monoclonal antibodies patients with metastatic colorectal cancer. In this prospective phase II clinical trial single-agent cetuximab
Objective Regorafenib demonstrated efficacy in patients with metastatic colorectal cancer (mCRC). Lack of predictive biomarkers, potential toxicities and cost-effectiveness concerns highlight the unmet need for better patient selection. Design Patients RAS mutant mCRC biopsiable metastases were enrolled this phase II trial. Dynamic contrast-enhanced (DCE) MRI was acquired pretreatment at day 15 post-treatment. Median values volume transfer constant (K trans ), enhancing fraction (EF) their...
There are limited data on circulating, cell-free, tumour (ct)DNA analysis in locally advanced rectal cancer (LARC). Digital droplet (dd)PCR was used to investigate KRAS/BRAF mutations ctDNA from baseline blood samples of 97 LARC patients who were treated with CAPOX followed by chemoradiotherapy, surgery and adjuvant ± cetuximab a randomised phase II trial. KRAS mutation G12D, G12V or G13D detected the 43% 35% tumours that mutant wild-type for these hotspot mutations, respectively, according...
Abstract Purpose: Anti-EGFR mAbs are effective in the treatment of metastatic colorectal cancer (mCRC) patients. RAS status and tumor location (sidedness) predictive markers patients' response to anti-EGFR mAbs. Recently, low miR-31-3p expression levels have been correlated with clinical benefit from mAb cetuximab. Here, we aimed validate power a prospective cohort chemorefractory mCRC patients treated single-agent Experimental Design: was tested by situ hybridization (ISH) 91 pretreatment...
A significant proportion of patients undergoing radical nephrectomy (RN) for clear-cell renal cell carcinoma (RCC) develop chronic kidney disease (CKD) within a few years following surgery. Chronic has important health, social and economic impact no predictive biomarkers are currently available. MicroRNAs (miRs) small non-coding RNAs implicated in several pathological processes. Primary objective our study was to define miRs whose deregulation is CKD treated with RN. Ribonucleic acid from...
To compare revised Choi criteria that incorporate concurrent size and attenuation changes at early follow-up imaging with Response Evaluation Criteria in Solid Tumors ( RECIST ) 1.1 original stratification of clinical outcomes patients metastatic renal cell carcinoma mRCC treated sunitinib.
BackgroundPatients often ask oncologists how long a cancer has been present before causing symptoms or spreading to other organs. The evolutionary trajectory of cancers can be defined using phylogenetic approaches but lack chronological references makes dating the exact onset tumours very challenging.Patients and methodsHere, we describe case colorectal (CRC) patient presenting with synchronous lung metastasis metachronous thyroid, chest wall urinary tract metastases over course 5 years. was...
Single nucleotide polymorphisms (SNPs) in microRNA genes have been associated with colorectal cancer (CRC) risk, survival and response to treatment. Conflicting results are available on the association between rs4919510, a SNP mature miR-608 clinical outcome CRC. Here, we analyzed rs4919510 benefit from perioperative treatment randomised phase II trial of neoadjuvant Capecitabine Oxaliplatin (CAPOX) followed by chemo-radiotherapy, surgery adjuvant CAPOX ± Cetuximab high-risk locally advanced...
To introduce atraumatic (Sprotte) lumbar puncture needles and compare complication rates with traumatic (Quincke) needles.Complication associated needle use were retrospectively analysed over a four-week period. Atraumatic then implemented prospective analysis of the was undertaken for further six weeks.A single-centre acute neurology unit in London teaching hospital.Traumatic (n = 24 patients); 36 patients).Headache rates, over-the-counter medications, medical assistance, time off work,...
48, XXYY syndrome is a form of sex chromosome aneuploidy that affects between 1 in 18 000 to 40 males. It not inherited and diagnosed by karyotyping. has similarities 47, XXY Klinefelter9s syndrome, with tall stature, micro-orchidism, hypergonadotropic hypogonadism infertility However, patients also commonly have dental problems, tremor, attention deficit disorder, learning difficulties, allergies asthma. The tremor typically reported as an intention (in 71% aged >20 years 48), which...
Poorly differentiated cancers are a diagnostic and therapeutic challenge in oncology. New therapies needed for patients with poorly thyroid carcinoma (PDTC) or anaplastic cancer, as these often present advanced disease effective systemic treatment options currently limited. Epidermal growth factor (EGFR) mutations may occur PDTC more than previously thought. However, there fewer 6 cases reported the literature where EGFR tyrosine kinase inhibitors (TKIs) (such erlotinib gefitinib) were used...
Adenocarcinoma of the seminal vesicles is a very rare malignancy, with less than 100 cases reported worldwide. It documented to have poor prognosis, majority patients developing metastatic disease, most commonly in prostate, bladder and rectum. Currently there no standard treatment for disease limited reports radiotherapy, chemotherapy hormonal (anti-androgenic) therapy show that they are generally modest benefit. The association between malignancy an increased risk autoimmune vasculitis has...
Abstract Trastuzumab in combination with chemotherapy represents the standard of care HER2-positive advanced gastro-esphageal cancer (GOC), but development resistance limits response. MicroRNAs (miRs) modulate key pathways GOC. Identification miRs responsible for to HER2 inhibition may help stratify patients, predict response and define novel strategies restore drug sensitivity. A high-throughput LNA™ miR-inhibitor screen NCI-N87 HER2-negative FLO-1 GOC cell lines was performed order...
384 Background: Advanced oesophago-gastric cancers have showcased varied responses to immunotherapy based on biomarkers such as tumour mutational burden, microsatellite instability, and PD-L1 expression. However, these markers may not fully capture heterogeneity evolutionary dynamics. Hence, understanding the intricate relationship between immune selection, specifically dN/dS, 1 evolution is vital for devising personalized therapeutic strategies. Methods: In our phase 2 open label,...
419 Background: A predictive biomarker for resistance to trastuzumab in HER2 positive oesophago-gastric cancer would refine patient selection. Our preclinical studies suggest that patients with HIGH baseline plasma miR-148a-3p levels will experience shorter Overall Survival (OS), Progression Free (PFS), and worse Rates (PFR) than those LOW levels. Methods: This sub-study is a prospective analysis of samples advanced registered within Arm B1 the Phase 2 open label, multicentre, randomised...
This study aimed to identify microRNAs (miRs) as circulating biomarkers of resistance first-line trastuzumab-based therapy in advanced HER2-positive oesophago-gastric cancer patients. A high-throughput 1015 Exiqon miRCURY LNA™ microRNA inhibitor library screen was performed trastuzumab-treated NCI-N87 and HER2-negative FLO-1 cell lines. NanoString nCounter® miR analysis NCI-N87, FLO-1, MAGIC trial (ISRCTN93793971) formalin-fixed paraffin-embedded (FFPE) patient samples. MiR-148a-3p copies...